HC Wainwright Brokers Increase Earnings Estimates for ITOS

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities research analysts at HC Wainwright upped their Q2 2025 earnings estimates for shares of iTeos Therapeutics in a research note issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.82) per share for the quarter, up from their prior estimate of ($1.17). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.85) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($2.10) EPS.

A number of other analysts have also issued reports on the company. Leerink Partnrs lowered iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (down previously from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, Leerink Partners reiterated a “market perform” rating and set a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.86.

iTeos Therapeutics Stock Performance

ITOS stock opened at $7.97 on Friday. The company has a 50 day moving average price of $6.59 and a two-hundred day moving average price of $7.42. The stock has a market capitalization of $305.04 million, a P/E ratio of -2.53 and a beta of 1.39. iTeos Therapeutics has a one year low of $4.80 and a one year high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $42,000. CWM LLC boosted its holdings in shares of iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock valued at $51,000 after acquiring an additional 6,936 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after acquiring an additional 3,293 shares during the period. Paloma Partners Management Co bought a new stake in iTeos Therapeutics during the first quarter worth approximately $65,000. Finally, Forefront Analytics LLC bought a new stake in iTeos Therapeutics during the fourth quarter worth approximately $85,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insider Buying and Selling at iTeos Therapeutics

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. This trade represents a 23.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the sale, the insider now directly owns 2,108,594 shares in the company, valued at $16,995,267.64. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.